Anavex Life Sciences Corp Revenue and Competitors
Estimated Revenue & Valuation
- Anavex Life Sciences Corp's estimated annual revenue is currently $5.7M per year.
- Anavex Life Sciences Corp's estimated revenue per employee is $139,878
- Anavex Life Sciences Corp's total funding is $62.6M.
- Anavex Life Sciences Corp's current valuation is $1.1B. (January 2022)
Employee Data
- Anavex Life Sciences Corp has 41 Employees.
- Anavex Life Sciences Corp grew their employee count by 5% last year.
Anavex Life Sciences Corp's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Senior Project Manager | Reveal Email/Phone |
Anavex Life Sciences Corp Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Anavex Life Sciences Corp?
ANAVEX Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. ANAVEX portfolio involves new sigma receptor compounds (ligands) in preclinical stage that target diseases of the Central Nervous System (CNS) and Cancer. The company’s lead drug candidate ANAVEX 2-73, targeting Alzheimer’s disease (AD) will enter first Human Clinical Trials (HTC) by September. In parallel, another three of Anavex’s compounds (melanoma, prostate cancer and epilepsy) will reach final preclinical stage later this year.
keywords:Biotechnology
$62.6M
Total Funding
41
Number of Employees
$5.7M
Revenue (est)
5%
Employee Growth %
$1.1B
Valuation
N/A
Accelerator
Anavex Life Sciences Corp News
Anavex Life Sciences Corp. (NASDAQ:AVXL) Expected to Announce Earnings of -$0.16 Per Share. Posted by admin on Apr 21st, 2022.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors With Losses to Inquire About Securities Class Action...
NEW YORK, March 28, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.2M | 41 | 8% | N/A |
#2 | $4.8M | 41 | -52% | N/A |
#3 | $3.9M | 41 | 5% | N/A |
#4 | $7.5M | 41 | -40% | N/A |
#5 | $4.7M | 41 | 3% | N/A |